"...when we started the bavituximab program in the clinic we were really focused on the effects that we are seeing in pre-clinical studies primarily effects on vasculature and we knew there were some immune components but it was really thought to be more of a vascular acting agent.
I think that has completely changed now we have recognized that while there are effects on the vasculature those are downstream effects that are really mediated through inhibiting this early checkpoint."
News 
Market Data 
Discover 
AI
